Cambrian Biopharma

Cambrian Biopharma is an Aging Drug Discovery company founded in 2019 and based in New York, United States. It has raised $200M in total funding, most recently a Series C in 2021.

Founded in 2019 and based in New York, Cambrian Biopharma (Cambrian Bio) runs a distributed-development or 'PipeCo' model, akin to Roivant and atai, in which it builds and finances a portfolio of affiliate companies each pursuing a distinct biological driver of aging. The company was co-founded by CEO James Peyer and chairman Christian Angermayer. In October 2021 it closed an oversubscribed $100M Series C co-led by Anthos Capital and the SALT Fund, with participation from Apeiron Investment Group, Future Ventures, and Moore Capital, having raised over $200M across its portfolio programs. Its affiliates include Amplifier Therapeutics, Tornado Therapeutics, and Telos Biotech, with multiple assets advancing into clinical trials.

Pioneered a multi-asset holding-company structure purpose-built to de-risk and accelerate a broad pipeline of anti-aging therapeutics.

cambrianbio.com Aging Drug Discovery

United Statesprivate

At a glance

Total raised

$200M

last round series c

Headcount

51-200

approximate · public range

Headquarters

New York

United States

Founded

2019

7 years active

Status

Private

Aging Drug Discovery

Subsector

Funding history

Total raised

$200M

Rounds tracked

Latest stage

Series C

Date	Stage	Amount	Valuation	Lead investors
Oct 19, 2021	Series C	$100M	—	Anthos Capital, SALT Fund

Cambrian Biopharma

At a glance

Funding history

In the news

Human data validate Cambrian Bio’s aging target

Cambrian Bio reports positive early human trial results for prediabetes drug

Cambrian Bio to present promising data on new obesity and prediabetes drug

Watch

Leadership

Products

Distributed development (PipeCo) platform

Anti-aging therapeutic pipeline

Compare Cambrian Biopharma with